1. FRI0206 Abatacept (CTLA4-IG) suppresses T cell activation and reduces TH17 cells as well as plasma IL-6 in patients with rheumatoid arthritis. (23rd January 2014) Authors: Matsutani, T.; Li, Y.; Murakami, M.; Lee, H.-M.; Aoki, C.; Sekiguchi, M.; Matsui, K.; Kitano, M.; Namiki, M.; Ohmura, K.; Murakami, K.; Fujii, T.; Kuroiwa, T.; Shimaoka, Y.; Nakahara, H.; Maeda, K.; Irimajiri, S.; Funauchi, M.; Imura, Y.; Ikawa, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗